secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2026-04-27T23:59:59+00:00
Accession:  0001104659-26-048971
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet pivots to acne, pauses MASH; cash $104.5M; Phase 3 acne trial H2 2026
-----------------------------------------------------------------------------

- Preliminary cash balance $104.5M as of Mar 31, 2026; provides runway for strategic pivot.
- Phase 3 U.S. trial of denifanstat in moderate-to-severe acne planned for H2 2026, pending IND clearance.
- MASH development paused until non-dilutive funding secured; combination program with resmetirom ready for Phase 2.
- New CMO Andreas Grauer appointed; Phase 1 of TVB-3567 ongoing, Phase 2 acne trial targeted for H2 2026.
- Positive Phase 3 acne safety results from partner Ascletis in China reported Jan 2026 (n=240).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465926048971/0001104659-26-048971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465926048971/tm2612738d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-048971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer